1. Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-Neulasta® in the prophylactic treatment of chemotherapy-induced neutropenia. (February 2017) Authors: Waller, C.; Blakeley, C.; Pennella, E.; Bronchud, M.H.; Mattano, L.; Berzoy, O.; Voitko, N.; Adamchuk, H.; Zautashvili, Z.; Vinnyk, Y.; Nemsadze, G.; Dzagnidze, G.; Shparyk, Y.; Lytvyn, I.; Rusyn, A.; Popov, V.; Láng, I.; Sharma, R.; Baczkowski, M.; Kothekar, M. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗